NCT06061146View on ClinicalTrials.gov

Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2026

Conditions
Esophageal Cancer
Interventions
DRUG

Arm A

anti-PD-1 immunotherapy

DRUG

Arm A

chemotherapy

RADIATION

Arm A

Radiation Concurrent Radiation, 1.8Gy/f, 28f

DRUG

Arm B

chemotherapy

RADIATION

Arm B

Radiation Concurrent Radiation, 1.8Gy/f, 28f

Trial Locations (1)

300060

RECRUITING

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors
collaborator

Sichuan Cancer Hospital and Research Institute

OTHER

collaborator

Shanxi Province Cancer Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Hunan Cancer Hospital

OTHER

collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER